Goldman Sachs reiterated a Buy rating on Impax Laboratories (NASDAQ: IPXL) with a price target of $29. Earlier it announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE